Biorasi is a catalyst for growth, innovation and evolution in the field of clinical research. We move the industry forward, improving results for our partners, and outcomes for their patients.
BrightInsight, a Flex Company, provides the leading global regulated digital health platform for biopharma and medtech. Our medical-grade Internet of Things (IoT) platform is built under a Quality Management System to support and optimize regulated drugs, devices and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement.
The BrightInsight™ Platform uses software and services to capture, transmit and analyze data from CE-marked and FDA-regulated medical devices, combination products, apps and Software as a Medical Device, in compliance with security, privacy and regulatory requirements.
Our name stems from “envoy,” which means “one undertaking a diplomatic mission.” As a Diplomat company, EnvoyHealth delivers customized services to help bridge the gap between small to midsize manufacturers and their patients. This promotes the development and success of innovative therapies and health technologies.
We set our sight on a simple, but powerful vision to advance life science services toward a healthier world.
The journey began when Water Street Healthcare Partners and JLL Partners joined forces to acquire and combine the most comprehensive platform of life sciences services in the industry. Together, we are EVERSANA.
We offer more than 500 clients – from start-ups to established global pharmaceutical leaders – the services they need to bring critical therapies to market while improving the lives of patients around the world.
IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes.
Noom is the world’s leading behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of over 1,000 personal coaches, Noom helps people live healthier lives by changing their habits for the long-term. More than 50 million people have benefited from Noom’s behavior change courses.
The company is headquartered in New York City with offices in Seoul and Tokyo.
Yes Health prevents chronic conditions, including diabetes and obesity, empowering people everywhere to take charge of their health—and have fun doing it. Our all-mobile platform delivers a highly personalized experience to each member by harnessing the expertise of our coaches and the power of artificial intelligence. Members lose more than 5% of their starting weight and regularly exercise 150 minutes or more every week. We partner with large health plans, including Blue Shield of California, to help keep their members healthy.
Our headquarters are in Mill Valley, California.
Curebase runs distributed clinical trials using technology to enroll and manage patients wherever they live. Our eClinical platform is built for remote research with online consent, remote monitoring, and at-home data capture with surveys and biometrics. We have experience executing four major digital therapeutic trials including one FDA pivotal study.
Empowering life sciences companies to innovate better and faster with streamlined software solutions for quality management systems
& regulatory submissions. Developed by a team with first-hand experience leading quality management, spearheading product development, and enduring regulatory audits, Enzyme simplifies and expedites tedious document preparation— saving time, enhancing accuracy, & reducing risk.
Virgin Pulse is the world’s largest, most comprehensive digital health, wellbeing and engagement company. Focused on driving personalized behavior change and results for individuals and organizations around the world, the company delivers the industry’s only fully integrated digital platform, with benefits navigation and live coaching to support global clients and members across the entire health, wellbeing and benefits lifecycle.
ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 35 years of experience and 7,000-plus ZSers in more than 25 offices worldwide, we are passionately committed to helping companies and their customers thrive.
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes.
Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.
Cognoa’s digital diagnostics and personalized therapeutics improve the timeliness, scale, and effectiveness of behavioral healthcare. Their first clinically-validated mobile application identified autism on average 13 months earlier than the national average and as early as 18 months – when early intervention has the greatest potential for improved life-long outcomes.
JAZZ Venture Partners invests in companies that extend the boundaries of human performance — improving how we live, learn, work, play, and experience the world.
We seek breakthroughs at the intersection of digital technology and neuroscience that are influencing the human experience, such as augmented reality, artificial intelligence, immersive gaming, and closed-loop human-computer systems.
Our portfolio companies are unlocking human potential in health, mind-body wellness, accelerated learning and training, sports, entertainment, and the enterprise.
Sanofi Digital Medicine, under the Chief Medical Office, improves patient outcomes through the development of innovative technology-driven solutions that when combined with drugs, improve treatment efficacy, safety, adherence and overall experience.
Be part of the 300+ person audience of senior executives who are driving forward the development of Digital Therapeutics
Learn from the industry-defining speaker faculty, comprised of the pioneers of the industry and the most exciting new-comers
Established in 2017, the DTx series is the home for the Digital Therapeutics community
The DTx Series is my go-to place for staying up-to-date and meeting all of the key players in this promising new digital health category.
I am excited to attend DTx for the fourth time. Whether as a presenter or part of the audience, I learn so much from other Digital Therapeutic executives and attendees about topics ranging from clinical trials to commercialization and everything in between.
I have been to the two editions of DTx West and I’m looking forward to attending DTx East this year. The conference brings together key leaders from across the digital health space to discuss new ideas and ongoing trends that are useful takeaways to bring back to my team.
“Thanks for catalyzing the industry forward in this emerging field. Looking forward to the next one”
“The DTx Series is a fantastic set of meetings. The quality of the investors, entrepreneurs and companies never fails to impress me, and I always leave having learned a lot”
“DTx is an inclusive event, where the participants truly believe that the rising tide will raise all boats”
“DTx is a great event! there is a great mix of digital innovators and large companies which deliver high-quality content. I learn a lot and it’s great to see this community come together and have authentic interactions”
As President and CEO, Kevin leads the Welldoc® team in the development and commercialization of innovative digital therapeutics for people living with chronic disease. Kevinhas over 25 years of experience in the life sciences sector including biotech, pharmaceuticals, hospital supplies and digital health. Prior to joining Welldoc, he held senior executive roles at Human Genome Sciences, Genentech and Abbott after starting his career at Baxter Healthcare.
As Strategic Account Executive, Payer Contracting, Dale is responsible for working with government, private and commercial insurance payers to maximize reimbursement and ensure compliance to contracted requirements. This includes rate and fee negotiations with the various payers and aligning payer network strategy to meet the needs of the client.
Dale has over 40 years of experience in the pharmacy industry. He has held various positions in the retail chain pharmacies and pharmacy benefit management companies related to provider contracting, contract compliance and performance. In addition, he has extensive background in pharmacy dispensing system management and workflow.
Dale received a Bachelor of Science Degree in Pharmacy from Ferris State University and is a licensed pharmacist in the State of Michigan. He has been involved with various industry and trade groups over the years, including the National Council of Prescription Drug Programs, (NCPDP) for more than 25 years.
Trina has built an extensive career in addressing prevention, wellbeing, behavior change, and emotional health by translating evidence into practice in healthcare in Ireland and the USA. Trina has been working in the digital space since 2010.
Trina is a Senior Principal Consultant in Prevention, Wellness, and Digital Health at Kaiser Permanente’s Care Management Institute. Trina obtained a Ph.D. in health psychology from University College Cork, Ireland. Trina has published on the topic of Obesity and has spoken at numerous conferences. Trina has consulted on games for health, including Kaiser Permanente’s “Amazing Food Detective” and on tech solutions for weight management (Picture it!) in collaboration with Ayogo. Trina is currently co-lead for Project Chamai (Greek for “grounded”) to deploy an ecosystem of digital mental health tools in Kaiser Permanente to support emotional wellness.
Trina has been invited to act as an expert advisor and to educate numerous organizations, including the Centers for Disease Control, CMS, National Committee for Quality Assurance (NCQA), National Quality Forum (NQF), Prescription for Physical Activity Task Force, and the Obesity Society and Ayogo. Trina is a member of the Society for Behavioral Medicine (SBM), the American Psychological Association (APA), The Obesity Society (TOS), and Digital Medicine Society (DiME).
Trina enjoys bringing the evidence to life for front line teams and implementing technology solutions to support people on their journey toward health.
As Vice President, Natasha leads EnvoyHealth, a digital therapeutic commercial services organization. EnvoyHealth was the first to support software prescribed like a medication or medical device. Envoy leverages a deep expertise in patient and provider services and pharmacy operations in order to partner with digital therapeutics manufacturers to provide comprehensive customer services, reimbursement support and product dispensing.
Natasha is uniquely positioned to lead the development and growth of digital therapeutics commercial and patient and provider services, having spent the last several years working side by side with pharmaceutical and biotechnology clients to build, launch, and manage innovative and comprehensive patient support programs that span the access, reimbursement, and adherence spectrum. Her specialty is constructing programs that question the status quo of the healthcare customer experience to deliver a thoughtful and tailored solution for each product’s commercial and customer needs, while balancing the long-term scalability of the operating model. She brings a background in data analytics, project management, corporate strategy, and operations to build strong teams, unified by a larger mission to change healthcare and impact patient lives.
Natasha received a Bachelor of Arts Degree in Foreign Affairs and Economics from the University of Virginia. She completed additional post-graduate coursework in the sciences from the University of Pennsylvania and holds a Project Management Professional® designation. Natasha actively serves and supports volunteer programs that focus on public health and economic empowerment.
Dr. Rosner is a digital health expert, researcher, entrepreneur, and practicing hospital-based physician. He publishes and speaks extensively on the use of digital health technologies in improving the four pillars of the quadruple aim. Prior to CLIIR, Dr. Rosner was the founding Chief Medical Information Officer of HealthLoop, a prominent digital patient engagement company. He has worked closely with top leadership at CMS, and was the lead author of an Improvement Activity in the Merit Based Incentive Payment System (MIPS) of CMS’ Quality Payment Program.
Dr. Rosner has collaborated with thought leaders and C-suite executives at top healthcare systems throughout the country implementing and evaluating the efficacy of digital health tools. He serves as an adviser to non-profits including the Network of Digital Evidence and the Digital Therapeutics Alliance, and sits on the Advisory Board of the Journal of AI and Healthcare. He founded two large national consortia on patient generated health data and on a metric for patient engagement with leaders from prominent organizations including the American Medical Association, CMS, the American Heart Association, HIMSS, the American College of Surgeons, and others. He is a cited domain expert in Participatory Healthcare, and frequently presents his research at academic and specialty organization conferences.
Dr. Rosner hold a PhD in engineering, and an MD from the University of Minnesota.
Elan is a Principal with JAZZ Venture Partners focused on technologies that unlock human potential, particularly in healthcare. JAZZ is a mid-sized traditional venture capital firm typically leading Series A rounds. Previously Elan grew several venture-backed startups as an operator and adviser across digital health, neuroscience, and AI, including co-founding Swing Therapeutics and Blue Note Therapeutics. Other past experiences include the Boston Consulting Group and Monitor Deloitte, where he incubated startups and advised executives. He received his bachelor’s degree from Tufts University and his MBA from the University of California, Berkeley.
Paul has over 10 years’ experience in the pharmaceutical, medical device and digital health industries.
Paul’s career began as a management consultant for the leading global life science consulting firm, Campbell Alliance (now Syneos Health) where he spent 4 years supporting global pharma and medtech clients, including leading numerous digital health initiatives. Paul then co-founded Nurep, a digital health startup with a vision of disrupting the $30B medical device sales rep market. Paul took Nurep from concept to clinical validation over 5 years in partnership with a large academic medical center and a leading medical device company while raising a large seed round of funding from top early-stage investors. After Nurep, Paul was an entrepreneur-in-residence at Stanford StartX Med, the Stanford-affiliated startup accelerator, supporting their Med portfolio with strategic initiatives and partnerships.
Paul is now the Senior Director of Commercial Development at BrightInsight, leading the partnership with Google and business development focusing on U.S. west and mid-west accounts.
Paul holds a Master’s in Business and Science from Keck Graduate Institute, a member of the Claremont Colleges, and a Bachelor of Science in Biotechnology from Washington State University.
Saeju Jeong, CEO and co-founder of Noom, is a serial entrepreneur and tech company angel investor. Noom is the world’s largest behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of thousands of personal coaches, Noom helps people live healthier lives by changing their long-term habits. More than 50 million people have benefited from Noom’s behavior change courses, and Noom’s platform is already being used by leading healthcare and pharmaceutical companies like Novo Nordisk to improve treatment outcomes for patients worldwide.
Noom, Inc. is backed by Sequoia Capital, RRE, Samsung and Qualcomm.
Jonathan has almost 20 years of experience helping biopharmaceutical companies make better strategic decisions in the areas of commercialization, research and development, portfolio planning, launch pricing and reimbursement, forecasting, asset valuation, and more across a broad range of therapeutic areas.
Jonathan’s experience spans both commercial and market-access questions and the development and application of both quantitative and qualitative insights. As such, he brings particularly deep expertise in leveraging innovative methodologies and large data sets to support analysis and strategic decision making.
He is an emerging leader in applying novel pricing methodologies to reimbursement for rare disease therapies. Jonathan has lectured on valuation approaches and techniques at the Massachusetts Biotechnology Council, and he co-authored “Biopharma: Beyond the First Product,” an in-depth look at critical success factors for growth of emerging biotechs, published in In Vivo.
Jonathan earned an MBA from Harvard Business School and a BA in economics from Dartmouth College.
Kara Tibbe leads health system wide care transformation initiatives centered around digital health innovation. At Spectrum Health, she leads projects focused on virtual and mobile health integration within primary and specialty care. Spectrum Health is the first health system in the US to integrate IQVIA’s App prescription platform “AppScript” into the EMR which enables mobile app prescriptions to be embedded into clinician workflow, a project that Kara leads. Kara’s role encompasses vetting digital therapeutics for employer and health care settings and operationalizing into seamless patient care.
Her background is in Business Administration and Science.
Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.
Elli Kaplan is the co-founder and CEO of Neurotrack. Her career spans two decades in the public and private sectors, including at the White House, the State and Treasury Departments, and the United Nations Development Program. Elli has also held positions with AIG, Goldman Sachs and multiple startups. She has won SXSW’s best new startup and DEMO God awards, the J&J World Without Disease Challenge, and presented at TEDx, TechCrunch Disrupt, the Royal Society of Medicine, Wired and the New York Times. Elli has an M.B.A. from Harvard Business School.
For more than two decades, Alex Petrov launched new businesses, built global consumer brands, and led high-performance teams at PayPal, Safeway and Nestlé. Yes Health was inspired in 2013 when Alex learned he was prediabetic and also discovered that 86 million people were in his same boat. He looked for a fun, motivating, and flexible program to help him make healthy changes. He didn’t find one, so he brought together a team of experts to start his own. Today, Yes Health has helped thousands of people prevent diabetes and lose weight with its fully CDC-recognized, all-mobile chronic disease prevention programs, featuring its revolutionary in-the-moment coaching.
Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.
Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.
Vasudev Bailey invests in disruptive healthcare (therapeutic, diagnostic, device, digital) companies as a Partner at ARTIS Ventures.
Previously, Vas helped found enterprise sales and the healthcare business for Quid.
Prior to ARTIS and Quid, Vas co-founded and served as the General Manager of the GLG Institute. In this role, he worked with Jeff Kindler (former CEO Pfizer), David Brennan (former CEO AZ), Shlomo Yanai (former CEO Teva) and Neil Golden (former CMO McDonald’s) and built a forum to connect retired C-suite executives with exceptional aspiring leaders.
Vas continues to draw on his strategy consulting background at McKinsey & Company as well as his experience from several acquired startups. He currently serves as an advisor to four startups and serves on ten boards.
Vas received his PhD in Biomedical Engineering from the Johns Hopkins School of Medicine where he was recognized as both a Siebel and a Medtronic Scholar. He holds four provisional patents from his research in nanotechnology for the early detection of cancer and has over thirty conference and journal publications. He graduated magna cum laude and Phi Beta Kappa from UC Irvine where he was also recognized as both a Regents and a Henry Samueli Scholar. Vas now sits on the Board of the Biomedical Engineering Department at Johns Hopkins University.
Jo is fascinated by the convergence of mobile technology and behavioral science, especially surrounding the area of healthcare. At 2Morrow, Jo leads the research and program development efforts to make evidence-based behavior modifications programs more accessible by putting them directly in the hands of those who need them via their smartphones. Focused on drivers that affect chronic disease (i.e. smoking, weight, stress, chronic pain management), 2Morrow’s evidence-based platform makes it easier and more convenient to include behavioral science into existing health care treatment plans. 2Morrow distributes programs distributed via employers, wellness platforms, health plans, providers and public health. Jo is a past “40 under 40“ who started her career as a nurse and has worked in healthcare, education and technologies companies.
Dr. Statake graduated from the Keio University School of Medicine. He engaged in clinical work at the Japanese Red Cross Society Medical Center, and was involved in the medical treatment of many patients as a respiratory physician. In 2012, he left the position to study abroad at the China Europe International Business School (CEIBS, Shanghai China) to gain global experience. He completed his MBA at the CEIBS and Masters of Public Health (MPH) from the John Hopkins University School of Public Health. He was engaged in medical informatics research at Johns Hopkins. After returning to Japan, he co-founded CureApp in 2014. He continues to see patients once a week to remain in the healthcare provider field.
Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.
Sharief Taraman, M.D. is the Chief Medical Officer at Cognoa, Inc., a Silicon Valley based startup that develops artificial intelligence-based digital diagnostics and personalized therapeutics that provide accurate, earlier diagnoses and more effective treatments to improve outcomes and lower behavioral healthcare costs. He is a Magna Cum Laude graduate of the University of Michigan having majored in Biochemistry. He completed his medical education at Wayne State University School of Medicine in 2006 and went on to complete residency training in Pediatrics and Pediatric Neurology at the Children’s Hospital of Michigan. Dr. Taraman is dual board certified in Neurology with special qualifications in child neurology from the American Board of Psychiatry and Neurology and in Clinical Informatics from the American Board of Preventative Medicine. He remains clinically active as the Division Chief of the CHOC Children’s Specialists Pediatric Neurology Division and a Health Sciences Associate Clinical Professor at UC Irvine School of Medicine. Dr. Taraman is active in the community as a board member of the AAP Orange County Chapter, Irvine Unified School District Medical Advisory Board, and volunteering for Girl Scouts of Orange County and the Capistrano Unified School District.
Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for panic disorder, panic attacks and PTSD. Debra has broad operational and leadership experience in start- ups, corporate and nonprofit organizations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor). Debra holds a B.A., MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of an HBS case study. Given her deep knowledge of digital therapeutics and medical devices, she is now an Advisor to DTxCC and a Consultant in this growing market.
Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.
As Vice President of R&D Solutions Strategy at IQVIA, Josh Rose is responsible for building the overarching strategy for the clinical development business, establishing and governing strategic initiatives, and leading the identification of acquisition candidates. He focuses specifically on bringing to market new solutions that drive growth and differentiation across the company. In 2018, Mr. Rose led the design and launch of IQVIA Virtual Trials, for which he now serves as Global Head leading efforts to expand this innovative offering to serve sponsors of all sizes and therapeutic areas of focus – small and large, local and global.
With nearly 20 years of experience in the biopharma, healthcare and technology industries, Mr. Rose has dedicated his career to product and marketing strategy development, across various sized companies, largely focused in healthcare services and technology. He began developing his strategic skills while working for Diamond Management, a technology focused management consulting firm later acquired by PWC. Mr. Rose went on to pursue leadership roles within companies including TriVirix, SciQuest and Hill-Rom. Since joining IQVIA in 2009 (then Quintiles), he has supported the exponential growth of the company as a strategy and marketing executive.
Mr. Rose earned his MBA from Duke University Fuqua School of Business and a B.S. in Chemical Engineering from the University of Illinois in Champaign-Urbana. Rose lives in Chapel Hill with his wife and three children, who all share a passion for the outdoors and participate in many sport activities.
Jeffrey has over 10 years’ experience in healthcare services/operations, market access, reimbursement, and HEOR. Jeffrey has worked both on the industry and consulting side of pharmaceuticals, medical devices, and diagnostics. His previous experience includes global work in the US, EU, and select APAC markets, covering 30 different products. Most recently he served as the Value Development Lead for The Medicines Company and their surgery/perioperative products. He was responsible for a value and evidence based approach to access and commercialization. He graduated from Boston University with a Bachelor of Health Sciences, Master of Science in Physical Therapy, and a Master of Business Administration.
Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA’s mission is to broaden the understanding, adoption, and integration of clinically-validated digital therapeutic solutions into mainstream healthcare through education, advocacy, and research.
With more than a decade of experience in the healthcare industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector, to the direct delivery of patient care. Prior to joining DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.
A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association.
Wayne Bowden is the Vice President of Program Development at Biorasi. Wayne oversees the design, development and optimization of Sponsor projects and serves as project director on various programs including: neurology, nephrology, rare disease, and digital therapeutics, in addition to Biorasi’s many clinical trial rescues.
Ross Muken is Chief Financial Officer at Click Therapeutics, where he works to guide Click’s future growth and financial strategy. Mr. Muken was previously Partner, Senior Managing Director and Head of the Healthcare Services & Technology Research Team at Evercore ISI, widely recognized as the #1 independent equity research franchise on Wall Street. He provided thoughtful insights on over 50 companies across the Healthcare Technology & Distribution, Life Science Tools & Diagnostics, Managed Care & Facilities and Medical Supplies & Devices sub-sectors. Ranked amongst the top analysts by Institutional Investor over the past decade, Mr. Muken is well-known for his proprietary fundamental research and highly accurate financial modeling as well as his work with emerging and disruptive technologies across the healthcare continuum. Prior to joining Evercore ISI, Mr. Muken served as a Managing Director at Deutsche Bank Securities, where he helped build the healthcare platform into a top franchise at the company. Previously, Mr. Muken spent time in the Equity Research division of Thomas Weisel Partners and began his career as an M&A Investment Banker at Bank of America Securities. Mr. Muken earned his B.S. in Business Administration, magna cum laude, at Boston University.
Pierre Leurent, CEO and founder of VOLUNTIS, has more than 19 years of international experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with therapeutic companion software. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Pierre worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions.
Women in DTx Drinks Evening
Join us for an evening of networking and to
celebrate the female success in this industry!
The Women in DTx Drinks Evening will take place the evening before the main summit, on Monday, February 17th from 5 – 7 PM at The Marriott, San Mateo Hotel.
This evening is free of charge and welcomes all who are a registered attendee of DTx West.
You can register your spot by emailing email@example.com.
Please note due to limited capacity, places are granted on a first-come, first-served basis.
Workshops - Thursday February 20th
- Workshop 1: The Business of Digital Therapeutics
- Workshop 2: Separating the Digital from the Traditional
Debra Reisenthel, Founding CEO, Palo Alto Health Sciences
Everett Crosland, SVP, Commercial, AppliedVR
Jonas Duss, US Chief Executive Officer, Kaia Health
Antoun Nabhan, VP, Corporate Development, Pear Therapeutics
- A brief overview of the various business models adopted by digital therapeutic companies
- An insight into the various routes to market
- Can DTx companies exist with both FDA and Non-FDA regulated therapeutics or do you have to “pick a side”
Splitting into smaller groups, you will discuss the intricacies of the business of digital therapeutics and hear views on how best to successfully run a business in the DTx industry.
- What are the current business models being used within the industry and which are demonstrating the most success?
- How do some business models favor certain types of digital therapeutic over others?
- Can a digital therapeutic company successfully develop and market both FDA & non-FDA regulated digital therapeutics?
- What are the route to market opportunities available to the DTx industry?
Representative(s) from each group share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised during this collaborative discussion.
Summary thoughts will then be shared by the moderator(s) and all participants will leave with the below:
- A deeper understanding of the various business models demonstrated by digital therapeutic companies
- Up-to-date information on business models of varying successes in the current industry
- A clear understanding of if it’s possible to successfully a dual entity business or if companies truly have to “pick a side”
- A clear understanding of current routes to market and their intricacies
- Your questions answered by industry leaders and your peers
Acacia Parks, Chief Scientist, Happify
Jenna Carl, VP of Clinical Development & Medical Affairs, Big Health
Derek Richards, Chief Science Officer, SilverCloud Health
- How do digital therapeutic clinical trials differ from traditional drug trials?
- An introduction of comparison groups and digital trial design
Led by leaders in the industry all with in-depth experience of DTx clinical trials, this panel will dive into clinical trial considerations when designing trials for digital therapeutics
- What are the requirements when designing digital therapeutic clinical trials?
- What does the FDA require from clinical trials for them to be acceptable?
- What does a SHAM/placebo look like in the DTx clinical trial?
- Should DTx companies and the FDA be working together to produce the right SHAM for each trial?
This is your chance to finalize your notes and prepare questions for the workshop leaders and your peers for after the break!
Splitting into smaller groups, each group will discuss their own views on digital therapeutic clinical trials and work on how best to move forward in this space.
- What are the current issues we face when designing clinical trials for digital therapeutics?
- What considerations should you have in mind when designing SHAM trials?
- What are the current guidelines for DTx clinical trials outlined by the FDA?
- How can we work with governing bodies to ensure DTx clinical trials are both suitable and feasible?
- What does a suitable and usable SHAM trial look like?
Representatives from each group will share their main points from their discussion with the whole workshop.
Workshop leaders and members from all groups will facilitate the discussion with their own thoughts and questions in this collaborative session.
Summary thoughts will be shared by workshop leaders and all participators will leave with the below:
- A clear understanding of the clinical trial landscape for digital therapeutics
- A deeper understanding of how best to build a SHAM/placebo for a DTx clinical trial
- An understanding of current FDA clinical trial guidelines in the space
- A greater understanding of important considerations to keep in mind when designing a DTx clinical trial
- Your questions answered by industry-leading experts and your peers
- Day 1: Tuesday, 18th February
- Day 2: Wednesday, 19th February
Adam Kaufman, President & CEO, Canary Health
Bryce Williams, VP, Lifestyle Medicine, Blue Shield of California
Alex Petrov, Founder & CEO, Yes Health
Kevin Appelbaum, Co-Founder & CEO, Better Therapeutics
Saeju Jeong, Co-Founder & CEO, Noom
Moderated by Brent Vaughan, Chief Executive Officer, Cognoa
Mette Dyhrberg, Founder & CEO, Mymee
Alex Waldron, Chief Strategy Officer, Pear Therapeutics
Peter Hames, Co-Founder & CEO, Big Health
Yasodhara Paruchuru, VP, Value & Access, Happify Health
Sponsored by Yes Health
Attendees are welcome to jump between tracks as they choose
Defining Evidence Standards for Digital Therapeutics
Chair: Acacia Parks, Chief Scientist, Happify
Acacia Parks, Chief Scientist, Happify
Josh Rose, VP and Global Head, IQVIA R&D Solutions Strategy, IQVIA Virtual Trials
Veena Rao, Senior Director, Search & Evaluation, Device Delivery, Connected Systems & Digital Health, Eli Lilly
Jonas Duss, US Chief Executive Officer, Kaia Health
Jo Masterson, Co-Founder. CPO & COO, 2morrow Inc.
Building the Value Proposition for Digital Therapeutics
Chair: Adam Kaufman, President & CEO, Canary Health
Andy Molnar, VP, Market Access & Trade, Cognoa
Jonathon Hodgson, Senior Principal, Promidian, an EVERSANA company
Jeff Abraham, VP of Market Access & Trade, Akili Interactive
Andy Molnar, Senior Director, Market Access, Cognoa
Kate Rosenbluth, Founder & CEO, Cala Health
Derek Richards, Chief Science Officer, Silvercloud Health
Wayne Bowden, VP, Program Development, Biorasi
Moderated by Sharief Taraman, Chief Medical Office, Cognoa
Debra Reisenthel, Founding CEO Palo Alto Health Sciences
Jenna Carl, VP of Clinical Development & Medical Affairs, Big Health
Megan Oser, VP of Clinical Innovation, Mahana Therapeutics
Marilen Abbago, Senior Virtual Trials Project Leader, IQVIA
Chris Wasden, Head of HappifyDTx, Happify Health
Mette Dyhrberg, Founder & CEO, Mymee
Melinda Decker, Principal, Digital Health Advisor
Mikael Eliasson, Global Head of Innovation, Neuroscience Product Development, Genentech
Dale Houston, Strategic Account Executive, Payer Contracting, Envoy Health
Natasha Mayfield, Vice President, Envoy Health
Moderated by Ed Cox, CEO, Dthera Sciences
Pierre Leurent, Founder and CEO, Voluntis
Paul Schultz, Senior Director, Commercial Development, BrightInsight
Matt Omernick, Founder & CCO, Akili Interactive
Megan Coder, Executive Director, Digital Therapeutics Alliance
Adam Kaufman, President & CEO, Canary Health
Sponsored by Virgin Pulse
Matthew Tucker, Head of Vital Program, Chief Marketing Officer, Highmark Health, NightWare
Chris Hogg, Chief Commercial Officer, Propeller Health
Timothy Kern, Vice President, Strategy & Business Development, ResMed
Moderated by Ross Muken, Chief Financial Officer, Click Therapeutics
Elli Kaplan, Co-Founder & CEO, Neurotrack
Chris Hogg, Chief Commercial Officer, Propeller Health
Kevin McRaith, President & CEO, Welldoc
Moderated by Elan Tye, Principal, JAZZ Venture Partners
Liz Rockett, Director, Kaiser Permanente Ventures
Vasudev Bailey, Partner, Artis Ventures
Ruchita Sinha, Venture Partner, AV8 Ventures
David Stevenson, Managing Director, Merck Global Health Innovation Fund
Mark Goad, Associate, OMERS Ventures
Siva Nadarajah, Co-Founder & President, JOGO Health
Kohta Satake, Co-Founder & CEO, CureApp
David Cox, Co-Founder & Chief Digital Officer, Closed Loop Medicine
Trina Histon, Senior Principal Consultant, Prevention, Wellness and Digital Health, Kaiser Permanente
Ben Rosner, Assistant Professor, UCSF
Rajan Merchant, Allergy, Asthma, and Clinical Immunology Specialist,Woodland Clinic Medical Group
Kara Tibbe, Training & Development Specialist, Spectrum Health
Pablo Panteoloni, VP & General Manager, Headspace Heath
Matthew Tucker, Head of Vital Program, Chief Marketing Officer, Highmark Health, NightWare
DTx West Venue - The Marriott, San Mateo
We strive to provide inspirational venues that can provide the space needed for an open and widely networked event.
The 2020 summit is back at the Marriott San Mateo, a contemporary hotel just 10 minutes from SFO airport. For 2020 space is bigger and better.
Blending the look and feel of a first class resort with comfort and state of the art conference amenities this venue is the perfect place for learning, networking and relaxing.
Bedrooms can be booked directly with the hotel. We anticipate high demand and recommend that you book early to secure the best possible rate. The Marriott does not offer an exclusive rate for DTx attendees. We have included, in the welcome pack, details of alternative hotels close to the DTx venue.
Partner with us
The DTx summits are the premier events for senior executives from DTx companies, Pharma, Investors, HCPs and Payers.
DTx West 2020 is the seventh summit in the DTx series. We are expecting 300 people at the summit in San Mateo, which is what our attendees and partners tell us is the optimum size
We believe that getting the right mix of partners is critical for a successful summit for you and our attendees. The DTx summit provides a rare opportunity to showcase your business to a world-class audience.
You will be impressed with our service and truthfulness. We will be honest with you throughout the process from deciding which option is right for you to delivery on-site.
Get in touch today to learn more and avoid missing out!
Register for the Event
For pricing and booking options please click the button to go to the registration page.